Published in
Taylor and Francis Group, OncoImmunology, 10(3), p. e958952
DOI: 10.4161/21624011.2014.958952
Links
- ORCID
- ORCID
- Taylor and Francis Group | PDF
- [espace.library.uq.edu.au]
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Co-blockade of immune checkpoints and adenosine A<sub>2A</sub>receptor suppresses metastasis
Journal article published in 2014 by
Arabella Young 
,
Deepak Mittal,
Kimberley Stannard,
Michelle Yong,
Michele Wl Teng,
Bertrand Allard,
John Stagg,
Mark J. Smyth
,
Deepak Mittal,
Kimberley Stannard,
Michelle Yong,
Michele Wl Teng,
Bertrand Allard,
John Stagg,
Mark J. Smyth
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Immunosuppressive pathways active within the tumor microenvironment must be targeted in combination to sufficiently bolster antitumor immune defenses. Inhibition of A2A adenosine receptor signaling in combination with immune checkpoint blockade enhances CD8(+) T and NK cell anti-metastatic activity. This results in reduced metastatic burden and improved survival in pre-clinical models.